SEP 3, 2026 · PHASE 1 TRIAL
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
ClinicalTrials.gov
This is a Phase 1 safety and pharmacokinetic study with no reported results; registry records of active or completed trials without posted outcomes represent early-stage work and cannot support efficacy or clinical claims.
Reported
Sample size34
PhasePhase 1
Primary outcome: Adverse events m…Up to approximately 297 days